New stent trial aims to stop second strokes in Hard-to-Treat carotid disease

NCT ID NCT07166731

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a stent (CARESTO® heal) plus standard medication against medication alone in 536 people who recently had a stroke or retinal artery blockage due to a specific type of carotid artery disease that is not severely narrowed. The goal is to see if the stent can lower the chance of another stroke or eye artery blockage over the medium and long term. Participants must have had their stroke within the last two weeks and have high-risk plaque features.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CARESTO® heal Stent (a carotid artery stent) plus medical management
What this could lead to
If successful, this could offer a new treatment option to reduce the risk of recurrent stroke in people with a specific type of carotid artery disease that is not currently treated with stents.
What could go wrong
This is a mid-stage trial with 536 participants, so results are not yet proven. Stenting carries risks like stroke, bleeding, or artery damage, and the benefit over medication alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 536 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with \<50% symptomatic non-stenotic carotid disease (SyNC) who were treated after randomisation by: Endovascular Treatment Group: Stenting + medical management o This group will be both given medical treatment according to standard clinical routine and treated by carotid artery stenting with the high coverage carotid stent (CARESTO® heal, Acandis® Pforzheim) Best medical treatment group: Medical management alone o This group will be given medical treatment according to standard clinical routine

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with acute ischemic stroke or acute retinal artery ischemia within the last two weeks related to symptomatic non-stenotic carotid disease (SyNC) and high-risk carotid plaque features * Ipsilateral acute ischemic stroke must be determined by acute ischemic infarct on DWI or CT OR * by neurological symptoms indicating ipsilateral cortical deficits consistent with ischemia in the territory of the internal carotid artery and after exclusion of a significant microangiopathy * Acute retinal artery ischemia must be determined by ophthalmologic examination * Patients with no other identifiable cause of stroke, evaluated using standard echocardiographic examinations to exclude cardiogenic or aortogenic sources of embolism * Symptomatic non-stenotic carotid disease defined as one or more plaques in the ipsilateral internal carotid artery causing 10-49% luminal narrowing AND * Presence of high-risk plaque features which must be determined through visual inspection on CTA or MRI (Ultrasound findings alone are insufficient; features must be confirmed by CTA or MRI to meet the criteria): * Identification of at least two of the following characteristics Plaque thickness ≥ 3mm Irregular plaque surface Ulceration \<50% plaque calcification Lipid-rich necrotic core * and/or identification of at least one of the following characteristics Intraplaque haemorrhage * Presence of carotid web characterized as shelf-like/linear, smooth filling defects * Plaque assessment including evaluation of the presence of high-risk features by routine imaging (CTA, MRI) confirmed by an independent CoreLab * Signed Informed Consent Form * Patient ≥ 18 years * mRS ≤ 3 at time of randomisation * Dual antiplatelet therapy (DAPT) according to standard of care before endovascular treatment Exclusion Criteria: * Patients with acute complete occlusion of the carotid artery in an emergency setting * Incidence of acute infarcts in other vascular (i.e., not ipsilateral carotid) territories * Patients in whom the stroke was likely caused by one of the following diseases: * Small vessel disease * Large vessel atherosclerotic disease ≥ 50% * Cardioembolism * Other known disease e.g. vasculitis * Predominantly calcified Plaques (≥50% calcified plaque components on CT-Angio) * Patients presenting with intraluminal carotid thrombus (e.g. characterized by 'donut sign' on CTA) * Patients with highly tortuous vessels (\>90°) which may prevent access or safe insertion of the stent * Patients with post-CEA re-stenosis or post-CAS re-stenosis * Patients with blood coagulation disorders * Patients in whom access to the carotid lesion is impossible or associated with an increased risk of procedural complications * Patients with lesions in the ostium of the common carotid artery * Patients with known hypersensitivity to nickel-titanium * Patients who are allergic to heparin * Any known conditions that affect life expectancy to less than 12 months * Any known conditions associated with an increased risk of endovascular treatment * Patients not able to visit the outpatient clinic for annual follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Städtisches Klinikum Solingen

    RECRUITING

    Solingen, North Rhine-Westphalia, 42653, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.